Lumida
/HUMA
⌘K
Humacyte Inc

Humacyte Inc

HUMA
$0.57USD+0.09%+0.00 today

MARKET CAP

157.7M

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$3

AI Summary

Stalk
Sell NowHigh

HUMA remains in a pronounced Stage 4 downtrend, characterized by a clear sequence of lower highs and lower lows on declining EMAs and a 200 SMA well above price. Trading near its 52-week low with muted volume on rallies, the medium- and long-term bias is strongly bearish. Short-term price action—tightly tracking below the 9- and 20-EMA and resting at an extreme oversold level—suggests selling is warranted now. A decisive close above the 50 SMA would invalidate this bearish view.

  • Interim Phase 3 results pave way for BLA submission later this year
  • Approval could unlock dialysis market revenue in regenerative medicine
  • Earnings yield of -2.85% and weak profitability hinder cash-flow generation
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2025TREND
Sales, Adj.$1.3M$1.6M$2.0M
YoY %+23.9%
P / Sales229.4x138.9x74.5x
EV / Sales187.0x99.1x105.3x
Gross Profit, Adj.$1.3M$1.6M$-7.7M
YoY %+23.9%
Margin %100.0%100.0%-376.1%
EV / Gross Profit187.0x99.1x-28.0x
EBITDA, Adj.$-72.9M$-76.3M$-102.8M
YoY %-4.7%+5.9%
Margin %-5774.0%-4876.9%-5044.6%
EV / EBITDA-3.2x-2.0x-2.1x
EBIT$-25.4M$-8.8M$-108.1M
YoY %+65.4%+5.5%
Margin %-2013.9%-563.0%-5306.0%
EV / EBIT-9.3x-17.6x-2.0x
Net Income$-26.5M$-12.0M$-40.8M
YoY %+54.8%+72.5%
Net Margin-2096.4%-764.5%-2003.6%
EPS (GAAP)-$0.66-$0.12-$0.26
YoY %+81.8%+79.4%